Abstract
The effect on the IGF system of 60 mg and 600 mg daily of raloxifene administered for 2 weeks prior to surgery was investigated in 37 postmenopausal women with breast cancer. Raloxifene significantly decreased insulin-like growth factor (IGF-I) as compared to placebo (P < 0.05) with no dose-response relationship. No significant change was observed in IGFBP-3, while the IGF-I/IGFBP-3 molar ratio was decreased by treatment, with a statistically significant effect only for the higher dose. Given that high plasma levels of IGF-I have been suggested as a risk factor for breast cancer, these findings provide further support for the potential activity of raloxifene in breast cancer prevention.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
-
Comparative Study
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Aged, 80 and over
-
Antineoplastic Agents, Hormonal / administration & dosage
-
Antineoplastic Agents, Hormonal / pharmacology*
-
Antineoplastic Agents, Hormonal / therapeutic use
-
Breast Neoplasms / blood*
-
Breast Neoplasms / drug therapy
-
Breast Neoplasms / surgery
-
Chemotherapy, Adjuvant
-
Depression, Chemical
-
Dose-Response Relationship, Drug
-
Female
-
Humans
-
Insulin-Like Growth Factor Binding Protein 3 / blood*
-
Insulin-Like Growth Factor I / analysis*
-
Mastectomy
-
Middle Aged
-
Neoplasm Proteins / blood*
-
Postmenopause
-
Premedication
-
Raloxifene Hydrochloride / administration & dosage
-
Raloxifene Hydrochloride / pharmacology*
-
Raloxifene Hydrochloride / therapeutic use*
-
Selective Estrogen Receptor Modulators / administration & dosage
-
Selective Estrogen Receptor Modulators / pharmacology*
-
Selective Estrogen Receptor Modulators / therapeutic use
Substances
-
Antineoplastic Agents, Hormonal
-
Insulin-Like Growth Factor Binding Protein 3
-
Neoplasm Proteins
-
Selective Estrogen Receptor Modulators
-
Raloxifene Hydrochloride
-
Insulin-Like Growth Factor I